EHA 2023
Ziftomenib: A Promising New Treatment for NPM1-Mutated Acute Myeloid Leukemia
SG Tylor
Kura Oncology’s recent presentation at the European Hematology Association (EHA) 2023 conference highlighted the impressive clinical potential of ziftomenib in ...
Innate Pharma Showcases Breakthrough Tetra-Specific ANKET NK Cell Engager IPH6501 at the EHA 2023 Congress
SG Tylor
Source: Innate Pharma On June 10, 2023, Innate Pharma, a biopharmaceutical company, highlights the latest preclinical findings on IPH6501, a ...
Kura Oncology Unveils Promising Clinical Results of Ziftomenib, at the 2023 European Hematology Association (EHA) Congress
SG Tylor
Source – Kura Oncology Kura Oncology presented updated clinical data for its menin inhibitor, ziftomenib, at the 2023 European Hematology ...
Danicopan Shows Promise as an Add-On to Ultomiris or Soliris, Enhancing Hemoglobin Levels and Disease Control in PNH Patients
SG Tylor
Source – AstraZeneca Promising outcomes emerged from the pivotal Phase III ALPHA trial, revealing that danicopan, an investigational oral Factor ...
